<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652886</url>
  </required_header>
  <id_info>
    <org_study_id>B053205</org_study_id>
    <nct_id>NCT00652886</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions</brief_title>
  <official_title>Compare the Relative Bioavailability of Oxandrolone 10mg Tablets With That of OXANDRIN 10 mg Tablets Following a Single Oral Dose(1*10 mg Tablet) in Healthy, Adult Subjects Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -To compare the single dose bioavailability of Kali and BTG
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -To compare the bioavailability of Oxandrolone 10mg tablets with that of OXANDRIN 10mg
      tablets following a single -dose in healthy, adult subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>To Determine the Bioequivalence Under Fasting Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Kali's products under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received BTG products under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone</intervention_name>
    <description>Tablets, 10mg, single-dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Oxandrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrin</intervention_name>
    <description>tablets, 10mg, single-dose</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Oxandrolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject at least 18 years of age, may be male or they may be female who are
             unable to bear children.

          -  Each subject shall be given a general physical examination within 28days of the
             initiation study.

          -  At the end of the study, the subjects will have an exit evaluation consisting of
             interim history, global evaluation, and clinical laboratory measurements.

          -  Each female subject will be given a serum test as part of the pregnancy study
             screening process.

          -  Clinical laboratory measurements will include Hematology, Clinical Chemistry, Urine
             Analysis, HIV Screen,hepatitis-B, C screen and Drugs of abuse Screen

        Exclusion Criteria:

          -  Subjects with a history of alcoholism or drug addiction(during past 2 years), or
             serious gastrointestinal, renal hepatic or cardiovascular disease, tuberculosis,
             epilepsy. asthma, diabetes, psychosis or glaucoma will not be eligible for thsi study.

          -  Subjects with any history of breast or prostate cancer will not be eligible to
             participate in this study.

          -  Subjects who have a history of allergic response to the class of drug being tested
             will be excluded from the study.

          -  Subjects found to have urine/saliva concentration of any of the tested drugs will not
             be allowed to participate.

          -  Subjects who have taken any investigational drug within thirty days prior to the first
             dosing of the study will not be allowed to participate.

          -  Female subjects who are not able to bear children will not be allowed to participate.

          -  Female subjects with positive or inconclusive results will be withdrawn from the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Herrmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc</name>
      <address>
        <city>St.Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>April 3, 2008</last_update_submitted>
  <last_update_submitted_qc>April 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence, Oxandrolone,fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

